US Stock MarketDetailed Quotes
PIRS Pieris Pharmaceuticals
- 16.9825
- -0.3175-1.84%
Close Nov 4 16:00 ET
22.42MMarket Cap-884P/E (TTM)
17.3500High16.9700Low18.58KVolume17.2100Open17.3000Pre Close318.46KTurnover2.30%Turnover RatioLossP/E (Static)1.32MShares22.320052wk High1.20P/B13.72MFloat Cap6.200052wk Low--Dividend TTM808.13KShs Float780.0000Historical High--Div YieldTTM2.20%Amplitude6.2000Historical Low17.1380Avg Price1Lot Size
Pieris Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 88.98%-1.48M | 36.38%-7M | 10.20%-53.82M | -52.08%-19.67M | -10.77%-9.72M | 13.78%-13.43M | 51.44%-11M | -682.40%-59.93M | -18.17%-12.93M | 39.40%-8.78M |
| Net income from continuing operations | -190.29%-3.59M | 62.89%-4.89M | 26.25%-24.54M | 43.42%-4.58M | -10.44%-10.75M | 138.46%3.98M | -158.44%-13.18M | 27.24%-33.28M | 15.00%-8.1M | 41.12%-9.74M |
| Operating gains losses | ---- | ---- | 85.90%-53K | --0 | --0 | ---106K | --53K | ---376K | ---77K | ---339K |
| Depreciation and amortization | --0 | -105.25%-30K | -35.94%1.78M | -138.12%-223K | -8.29%708K | 24.36%725K | -32.02%571K | 17.40%2.78M | -0.51%585K | 31.74%772K |
| Other non cash items | -56.04%-284K | 1,868.06%1.42M | -36.26%-124K | 101.63%5K | -1,050.00%-19K | -247.97%-182K | -20.88%72K | -203.33%-91K | -448.21%-307K | -95.00%2K |
| Change In working capital | 111.60%2.19M | -752.88%-3.96M | -44.26%-48.14M | -139.71%-14.34M | -3,341.02%-15.52M | -159.26%-18.89M | 103.09%607K | -209.32%-33.37M | -83.24%-5.98M | -905.36%-451K |
| -Change in receivables | ---- | ---- | 302.25%5.31M | ---- | ---- | ---- | ---- | -44.73%-2.62M | ---- | ---- |
| -Change in prepaid assets | ---- | ---- | 174.96%1.02M | ---- | ---- | ---- | ---- | 56.94%-1.36M | ---- | ---- |
| -Change in payables and accrued expense | ---- | ---- | 61.95%-3.13M | ---- | ---- | ---- | ---- | -148.53%-8.21M | ---- | ---- |
| -Change in other current liabilities | ---- | ---- | -1,048.89%-11.37M | ---- | ---- | ---- | ---- | -0.20%-990K | ---- | ---- |
| -Change in other working capital | ---- | ---- | -98.00%-39.97M | ---- | ---- | ---- | ---- | -203.22%-20.19M | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 88.98%-1.48M | 36.38%-7M | 10.20%-53.82M | -52.08%-19.67M | -10.77%-9.72M | 13.78%-13.43M | 51.44%-11M | -682.40%-59.93M | -18.17%-12.93M | 39.40%-8.78M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 259.30%2.18M | -24.39%9M | 156.52%12M | 211.56%3.45M | -136.27%-1.98M | 87.43%-1.37M | 170.23%11.9M | -2,137.72%-21.24M | 423.68%1.11M | 1,662.86%5.47M |
| Net PPE purchase and sale | --0 | --0 | 83.57%-171K | 18.18%13K | -102.94%-69K | 89.35%-67K | 87.66%-48K | -9.69%-1.04M | 103.22%11K | 90.29%-34K |
| Net investment purchase and sale | 267.51%2.18M | -24.69%9M | 160.28%12.17M | 213.50%3.44M | -134.79%-1.92M | 87.31%-1.3M | 172.17%11.95M | ---20.2M | --1.1M | --5.5M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 259.30%2.18M | -24.39%9M | 156.52%12M | 211.56%3.45M | -136.27%-1.98M | 87.43%-1.37M | 170.23%11.9M | -2,137.72%-21.24M | 423.68%1.11M | 1,662.86%5.47M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 174.40%19.8M | -84.95%14K | 0 | -87.80%7.21M | -98.10%93K | -98.71%282K | ||||
| Net common stock issuance | ---- | ---- | 185.02%19.73M | --0 | --0 | ---- | ---- | -87.88%6.92M | --0 | -98.68%282K |
| Proceeds from stock option exercised by employees | ---- | ---- | -77.40%66K | -84.95%14K | --0 | ---- | ---- | -85.59%292K | -60.43%93K | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | ---- | ---- | 174.40%19.8M | -84.95%14K | --0 | ---- | ---- | -87.80%7.21M | -98.10%93K | -98.71%282K |
| Net cash flow | ||||||||||
| Beginning cash position | -51.98%19.08M | -54.97%17.4M | -67.19%38.64M | -32.07%32.89M | -17.18%44.94M | -52.54%39.74M | -67.19%38.64M | 67.19%117.76M | -61.28%48.42M | -54.44%54.26M |
| Current changes in cash | -86.04%696K | 120.95%2M | 70.22%-22.02M | -38.12%-16.21M | -286.88%-11.71M | 119.05%4.98M | 102.75%907K | -246.39%-73.95M | -83.76%-11.73M | -142.73%-3.03M |
| Effect of exchange rate changes | -123.11%-49K | -258.00%-316K | 115.13%783K | -63.60%708K | 88.00%-337K | 106.39%212K | 120.12%200K | -62.23%-5.18M | 315.39%1.95M | -149.16%-2.81M |
| End cash Position | -56.09%19.73M | -51.98%19.08M | -54.97%17.4M | -54.97%17.4M | -32.07%32.89M | -17.18%44.94M | -52.54%39.74M | -67.19%38.64M | -67.19%38.64M | -61.28%48.42M |
| Free cash flow | 89.04%-1.48M | 36.65%-7M | 11.45%-53.99M | -52.11%-19.66M | -11.12%-9.79M | 16.71%-13.5M | 52.05%-11.04M | -608.25%-60.97M | -14.50%-12.92M | 40.60%-8.81M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data